Mechanisms of PSGL-1 restriction of HIV virion infectivity
PSGL-1限制HIV病毒粒子感染性的机制
基本信息
- 批准号:9927218
- 负责人:
- 金额:$ 38.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Amino AcidsAntiviral AgentsBindingBiological AssayCD4 Positive T LymphocytesCell membraneCell surfaceCellsClathrinDimerizationDisease remissionDown-RegulationE-SelectinEndotheliumExclusionExtracellular DomainGlycoproteinsHIVHIV InfectionsHIV-1ImmuneInfectionL-SelectinLeukocytesLinkLymphoid CellMediatingMembraneMucinsMutagenesisMyeloid CellsN-terminalNatural ImmunityP-SelectinP-selectin ligand proteinPathogenesisPathway interactionsPhenotypeProcessProteinsReceptor CellResidual stateRoleSiteStructureStructure-Activity RelationshipSurfaceTestingTissuesUbiquitinationViralViral PhysiologyViral reservoirVirionVirus Assemblybasedimerextracellularglycosylationmigrationnovel therapeutic interventionparticlereceptortraffickingtyrosine O-sulfateubiquitin-protein ligasevirus host interaction
项目摘要
Project Summary/Abstract
Mechanisms of PSGL-1 restriction of HIV virion infectivity
Restriction factors are an important component of host innate immunity. Studying the anti-HIV mechanisms of
restriction factors is central to understanding virus-host interaction. These mechanisms may also offer new
therapeutic strategies to inactivate viral reservoirs to achieve lasting HIV remission. Recently, we have
identified a new HIV restriction factor, PSGL-1 (P-selectin glycoprotein ligand-1), that can inactivate the
infectivity of HIV virions released from HIV producing cells. PSGL-1 is a dimeric mucin-like 120-KD
glycoprotein that is primarily expressed on the surface of lymphoid and myeloid cells. PSGL-1 binds to P-, L-,
and E-selectin, and mediates leukocyte tethering and rolling on endothelium for leukocyte migration into
inflamed tissues. PSGL-1 is also an INF-γ-regulated factor involved in Th1-mediated anti-viral activity. Our
preliminary mechanistic studies further revealed that PSGL-1 is incorporated into viral particles, which blocks
HIV Env incorporation and disables the ability of virions to attach to target CD4 T cells for infection. In
addition, we found that PSGL-1 is antagonized by Vpu and Nef through surface down-regulation. Based on
these preliminary studies, we hypothesize that: (1) PSGL-1-mediated restriction of HIV infectivity involves its
specific domains; (2) PSGL-1 restricts HIV infectivity likely through competitive exclusion of Env
incorporation during viral assembly and steric hindrance of Env binding to cell receptors (3) Nef-mediated
PSGL-1 down-regulation is likely achieved through linking PSGL-1 to components of clathrin-dependent
trafficking pathways. In this application, we will pursue the following aims: Specific Aim 1 is to characterize
PSGL-1 for inactivating HIV infectivity. We propose to identify PSGL-1 domains key to restricting HIV-1. We
will determine the structure-function relationship of PSGL-1, defining the roles of PSGL-1 dimerization, N-
terminal glycosylation and tyrosine sulfation, N-terminal decameric repeats, and the polybasic region in
restricting HIV. Specific Aim 2 is to perform mechanistic studies of PSGL-1 inactivation of HIV viral
infectivity. We hypothesized that PSGL-1 restricts HIV infectivity likely through two possible mechanisms: (1)
competitive exclusion of Env incorporation during viral assembly; (2) steric hindrance of residual Env binding
to cell receptors. We will test these two hypotheses to determine the mechanisms of action. Specific Aim 3 is to
study the mechanism of Nef-mediated surface down-regulation of PSGL-1. We will identify functional
domains of Nef and PSGL-1 for their involvement in PSGL-1 down-regulation. Nef-mediated PSGL-1
downregulation may facilitate viral spread in immune cells.
项目摘要/摘要
PSGL-1限制HIV病毒体感染的机制
限制因素是宿主先天免疫力的重要组成部分。研究的反HIV机制
限制因素对于理解病毒宿主相互作用至关重要。这些机制也可能提供新的
灭活病毒储存剂以实现持久的HIV缓解的治疗策略。最近,我们有
鉴定出一种新的HIV限制因子PSGL-1(P-选择蛋白糖蛋白配体1),可能使这种失活
HIV生产细胞释放的HIV病毒的感染性。 PSGL-1是二聚体粘蛋白样120-kD
糖蛋白主要在淋巴样和髓样细胞表面表达。 PSGL-1与p-,l-,
和E-选择蛋白,并介导白细胞的束缚和滚动,以将白细胞迁移到
发炎的组织。 PSGL-1也是涉及Th1介导的抗病毒活性的INF-γ调节因子。我们的
初步机械研究进一步表明,PSGL-1被纳入病毒颗粒中,该病毒颗粒阻碍了
HIV设想并禁用病毒附着于目标CD4 T细胞感染的能力。在
此外,我们发现PSGL-1通过表面下调通过VPU和NEF拮抗。基于
这些初步研究,我们假设:(1)PSGL-1介导的HIV感染限制涉及其
特定域; (2)PSGL-1限制了可能通过ENV的竞争性排除的艾滋病毒感染
在病毒组装和环境与细胞受体结合(3)NEF介导的掺入期间
PSGL-1下调可能是通过将PSGL-1与依赖网格蛋白依赖性的成分链接到的
贩运途径。在此应用中,我们将追求以下目的:特定目的1是表征
PSGL-1用于失活的HIV感染。我们建议确定限制HIV-1的PSGL-1域关键。我们
将确定PSGL-1的结构功能关系,定义PSGL-1二聚体的作用,n-
末端糖基化和酪氨酸硫酸化,N末端脱月重复序列以及多义区域
限制艾滋病毒。具体目的2是对HIV病毒的PSGL-1失活的机械研究
感染力。我们假设PSGL-1通过两种可能的机制限制了HIV感染:(1)
在病毒组装过程中的竞争性排除; (2)残留的环境障碍
到细胞受体。我们将测试这两个假设以确定作用机理。具体目标3是
研究NEF介导的PSGL-1表面下调的机制。我们将确定功能
NEF和PSGL-1的域,用于参与PSGL-1下调。 NEF介导的PSGL-1
下调可能促进免疫细胞中的病毒扩散。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUNTAO WU其他文献
YUNTAO WU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUNTAO WU', 18)}}的其他基金
Mechanisms of PSGL-1 restriction of HIV virion infectivity
PSGL-1限制HIV病毒粒子感染性的机制
- 批准号:
10366051 - 财政年份:2020
- 资助金额:
$ 38.68万 - 项目类别:
Mechanisms of PSGL-1 restriction of HIV virion infectivity
PSGL-1限制HIV病毒粒子感染性的机制
- 批准号:
10593948 - 财政年份:2020
- 资助金额:
$ 38.68万 - 项目类别:
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs
针对 SIV 巨噬细胞储库的 Rev 依赖性载体的验证
- 批准号:
8731441 - 财政年份:2014
- 资助金额:
$ 38.68万 - 项目类别:
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs
针对 SIV 巨噬细胞储库的 Rev 依赖性载体的验证
- 批准号:
9233206 - 财政年份:2014
- 资助金额:
$ 38.68万 - 项目类别:
Development of a novel HIV-1 nuclear localization assay
新型 HIV-1 核定位测定的开发
- 批准号:
8657743 - 财政年份:2014
- 资助金额:
$ 38.68万 - 项目类别:
Validation of the Rev-dependent vector for targeting SIV macrophage reservoirs
针对 SIV 巨噬细胞储库的 Rev 依赖性载体的验证
- 批准号:
9047312 - 财政年份:2014
- 资助金额:
$ 38.68万 - 项目类别:
Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin
开发用于抗 HIV 药物筛选的 HIV Rev 依赖性双报告细胞
- 批准号:
8138239 - 财政年份:2011
- 资助金额:
$ 38.68万 - 项目类别:
Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin
开发用于抗 HIV 药物筛选的 HIV Rev 依赖性双报告细胞
- 批准号:
8296270 - 财政年份:2011
- 资助金额:
$ 38.68万 - 项目类别:
Regulation of Cofilin in HIV-1 Infection of Human CD4 T Cells
Cofilin 在人类 CD4 T 细胞 HIV-1 感染中的调节
- 批准号:
8277404 - 财政年份:2009
- 资助金额:
$ 38.68万 - 项目类别:
Regulation of Cofilin in HIV-1 Infection of Human CD4 T Cells
Cofilin 在人类 CD4 T 细胞 HIV-1 感染中的调节
- 批准号:
7755791 - 财政年份:2009
- 资助金额:
$ 38.68万 - 项目类别:
相似国自然基金
核苷类抗病毒药物嵌合型核酸纳米载体的构筑及其抗病毒性能研究
- 批准号:52303174
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向病毒核衣壳蛋白质相分离的抗病毒药物发现及机制研究
- 批准号:82302491
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
水环境中抗病毒药物及其转化副产物的识别及生态毒性效应研究
- 批准号:52300245
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
猴痘病毒入侵融合复合物、DNA聚合酶复合物的结构解析以及抗病毒药物的开发
- 批准号:82241081
- 批准年份:2022
- 资助金额:65.00 万元
- 项目类别:专项项目
CCHFV的致病机理及抗病毒药物研究
- 批准号:U22A20336
- 批准年份:2022
- 资助金额:255.00 万元
- 项目类别:联合基金项目
相似海外基金
Investigating the molecular mechanisms of membrane remodeling by coronaviruses
研究冠状病毒膜重塑的分子机制
- 批准号:
10724399 - 财政年份:2023
- 资助金额:
$ 38.68万 - 项目类别:
Mechanisms of HIV fitness and drug resistance inferred from high-resolution molecular dynamics and sequence co-variation models
从高分辨率分子动力学和序列共变模型推断出 HIV 适应性和耐药性的机制
- 批准号:
10750627 - 财政年份:2023
- 资助金额:
$ 38.68万 - 项目类别:
Broad spectrum inhibitors of paramyxovirus envelope proteins
副粘病毒包膜蛋白的广谱抑制剂
- 批准号:
10634368 - 财政年份:2023
- 资助金额:
$ 38.68万 - 项目类别:
Exploring the dynamics of nsp1 and RNA interaction in SARS-CoV with undergraduate researchers
与本科生研究人员一起探索 SARS-CoV 中 nsp1 和 RNA 相互作用的动态
- 批准号:
10730676 - 财政年份:2023
- 资助金额:
$ 38.68万 - 项目类别:
First-in-human study of a potent anti-HBsAg neutralizing antibody
强效抗 HBsAg 中和抗体的首次人体研究
- 批准号:
10550458 - 财政年份:2023
- 资助金额:
$ 38.68万 - 项目类别: